Instrument Inactif

Autres langues TetraLogic Pharmaceuticals Corporation Other OTC

Actions

TLOG

US88165U1097

Recherche biotechnologique et médicale

Autres langues

26/02/21	MEDIVIR : YEAR-END REPORT JANUARY - DECEMBER 2020
11/12/20	Medivir : strengthens its business development possibilities through a renegotiated agreement with TetraLogic regarding birinapant
11/12/20	Medivir AB Renegotiates its agreement with TetraLogic Pharmaceuticals Corporation
18/01/17	TetraLogic Pharmaceuticals Corporation Appoints Alexandre Zyngier to Board of Directors and Management
29/12/16	Tetralogic Pharmaceuticals Corporation Announces Management Resignations
29/12/16	Medivir AB (OM:MVIR B) completed the acquisition of substantially all the assets of TetraLogic Pharmaceuticals Corporation.
07/11/16	TetraLogic Pharmaceuticals Corporation(OTCPK:TLOG) dropped from S&P TMI Index
03/11/16	TetraLogic Pharmaceuticals Corporation(OTCPK:TLOG) dropped from NASDAQ Composite Index
02/11/16	Medivir AB (OM:MVIR B) entered into a definitive asset purchase agreement to acquire substantially all the assets of TetraLogic Pharmaceuticals Corporation for approximately $170 million.
22/07/16	TetraLogic Pharmaceuticals Corporation Announces Resignation of Douglas Reed as M. D, Effective July 21, 2016
07/04/16	TetraLogic Pharmaceuticals Corporation Announces Executive Changes
21/03/16	TetraLogic Pharmaceuticals Corporation(NasdaqGM:TLOG) dropped from CRSP US Total Market Index
16/03/16	TetraLogic Pharmaceuticals Corporation Auditor Raises 'Going Concern' Doubt
03/02/16	TetraLogic Pharmaceuticals Corporation Announces Resignation of Douglas E. Onsi as Member of Board of Directors, Effective February 5, 2016
22/01/16	TetraLogic Pharmaceuticals Corporation Announces Management Terminations; Authorizes the Implementation of a 19 Person Reduction in Staff
06/01/16	TetraLogic Pharmaceuticals Corporation Announces Results of the Interim Analyses of Two Clinical Studies
09/12/15	TetraLogic Pharmaceuticals Corporation Announces Resignation of Michael Steinmetz from the Board of Directors, Effective December 15, 2015
04/11/15	TetraLogic Pharmaceuticals Corporation Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Provides Update on SHAPE Alopecia Areata Program
05/08/15	TetraLogic Pharmaceuticals Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
30/07/15	Certain shares of TetraLogic Pharmaceuticals Corporation's Common Stock are subject to a Lock-Up Agreement Ending on 30-JUL-2015.
20/07/15	TetraLogic Pharmaceuticals Corporation Provides Update on Hepatitis B Clinical Program
30/04/15	TetraLogic Pharmaceuticals Mulls Acquisitions
21/04/15	TetraLogic Announces Publication of Two Papers Describing Birinapant's Preclinical Activity in Chronic Hepatitis B
20/04/15	TetraLogic Pharmaceuticals Corporation and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA(R) (Pembrolizumab) in Solid Tumors
20/04/15	TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA(R) (pembrolizumab) in Solid Tumors